FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

1217217003: Tenofovir disoproxil phosphate (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 30-Apr 2022. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
5035170010 Tenofovir disoproxil phosphate (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
5035171014 Tenofovir disoproxil phosphate en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Tenofovir disoproxil phosphate (substance) Is a Reverse transcriptase inhibitor true Inferred relationship Some
Tenofovir disoproxil phosphate (substance) Is a Carboxylic ester (substance) true Inferred relationship Some
Tenofovir disoproxil phosphate (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Reverse transcriptase inhibitor (disposition) true Inferred relationship Some
Tenofovir disoproxil phosphate (substance) This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. Tenofovir disoproxil (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Efavirenz 600 mg and emtricitabine 200 mg and tenofovir disoproxil (as tenofovir disoproxil phosphate) 245 mg oral tablet The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Tenofovir disoproxil phosphate (substance) Inferred relationship Some 3
Product containing precisely tenofovir disoproxil (as tenofovir disoproxil phosphate) 245 milligram/1 each conventional release oral tablet (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Tenofovir disoproxil phosphate (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start